Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

130.40 -0.04 (-0.03%)
Official Closing Price Updated: 1:10 PM EST, Nov 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
52 53 Next >
News headline image
Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst ↗
Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks. 
Via Benzinga
Topics World Trade
News headline image
3 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year ↗
FDA grants accelerated approval to Novartis' Vanrafia for IgA nephropathy, with Phase 3 data in 2026 expected to support traditional approval. 
Via Benzinga
News headline image
Novartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug Approval ↗
The companies are going head to head in kidney disease. Here's why Novartis could have a slight advantage. 
Via Investor's Business Daily
News headline image
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals ↗
Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction. 
Via Benzinga
News headline image
Is the Market Bullish or Bearish on Novartis? ↗
 
Via Benzinga
News headline image
The Top 3 Vanguard ETFs of 2025 (so Far) Share This 1 Striking Common Denominator ↗
Via The Motley Fool
Topics Bonds ETFs
News headline image
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) Technical Analysis observations. ↗
Exploring NOVARTIS AG-SPONSORED ADR's Technical Signals and Breakout Potential: Promising Signs: NOVARTIS AG-SPONSORED ADR Setting the Stage for a Breakout. 
Via Chartmill
News headline image
No Fear And No Panic After A 10% Correction = No Bottom ↗
In this video lesson, I discuss the overall market, my books, and my game plan moving forward after Friday's ugly sell-off. 
Via Talk Markets
Topics Stocks / Equities
News headline image
FDA OKs Novartis Prostate Cancer Treatment, Triples Eligible Patient Pool ↗
FDA approves Novartis' Pluvicto for advanced prostate cancer patients who have received ARPI therapy. 
Via Benzinga
News headline image
Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements
EQNX::TICKER_START (NYSE:ATNM),(NYSE:BMY),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) is an undervalued gem with solid fundamentals. ↗
NOVARTIS AG-SPONSORED ADR has caught the attention as a great value stock. NYSE:NVS excels in profitability, solvency, and liquidity, all while being very reasonably priced. 
Via Chartmill
News headline image
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga
News headline image
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease ↗
Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory reviews continue. 
Via Benzinga
News headline image
Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders ↗
Monte Rosa's MRT-6160 shows promising Phase 1 results, with Novartis backing its development in a deal that could reach $2.1B in milestone payments. 
Via Benzinga
News headline image
Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy ↗
Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a treatment option. 
Via Benzinga
News headline image
The Best Vanguard ETF to Invest $1,000 in Right Now ↗
Via The Motley Fool
Topics ETFs
News headline image
These 2 Vanguard ETFs Are Crushing the S&P 500 in 2025. Should You Buy? ↗
Via The Motley Fool
Topics ETFs Stocks
News headline image
Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound For Weight Loss ↗
Teladoc Health teams up with Eli Lilly's LillyDirect to improve Zepbound access, offering direct home delivery and comprehensive obesity care support. 
Via Benzinga
News headline image
Novartis Earns Near-Best Overall Rating As Profit Growth Climbs ↗
Novartis ranks No. 1 among in the 33-stock Medical-Ethical Drugs industry group. Novartis got a Composite Rating upgrade to 96 on Wednesday. 
Via Investor's Business Daily
News headline image
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) stands out as a stock that provides good value for the fundamentals it showcases. ↗
Uncover the potential of NOVARTIS AG-SPONSORED ADR, an undervalued stock. NYSE:NVS maintains a strong financial position and offers an appealing valuation. 
Via Chartmill
News headline image
Novartis Earnings Surprised The Street; Still Going Strong Despite Market Correction ↗
Highly ranked Novartis is forming the right side of a long cup base with a buy point of 120.92. And it's literally running higher. 
Via Investor's Business Daily
News headline image
Roche Touts Food Allergy Drug As Superior Than Oral Immunotherapy ↗
Roche's Xolair outperformed oral immunotherapy in a Phase 3 trial for food allergies, showing better tolerance and fewer adverse events. 
Via Benzinga
News headline image
3 Dividend Stocks That Are No-Brainer Buys Right Now ↗
Via The Motley Fool
News headline image
Court Dismisses Novartis Challenge To Medicare Drug Price Negotiation Program ↗
A federal court rejected Novartis' legal challenge to the Medicare Drug Price Negotiation Program, ruling that it does not impose unconstitutional fines, takings, or compelled speech. 
Via Benzinga
News headline image
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects ↗
Multiple sclerosis patients report severe side effects, including relapses and mobility issues, after switching from Tysabri to Tyruko in an NHS cost-saving move. Regulators and experts are assessing... 
Via Benzinga
News headline image
This Kraft Heinz Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday ↗
 
Via Benzinga
News headline image
Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal ↗
Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late-stage anticoagulant, to its cardiovascular portfolio. 
Via Benzinga
News headline image
Super Bowl Commercials 2025: Complete List of Super Bowl LIX Ads And Companies Behind Them ↗
The list of Super Bowl LIX commercials and the companies behind the Super Bowl ads. 
Via Benzinga
News headline image
Super Bowl LIX Commercials: AI, Celebs, Muppets, Warren Buffett-Linked Brand Take The Spotlight ↗
A list of Super Bowl LIX commercials and the celebrities and athletes attached to star in the ads. 
Via Benzinga
Topics Artificial Intelligence
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
52 53 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.